^
Association details:
Biomarker:BCL2 overexpression
Cancer:Acute Myelogenous Leukemia
Regimen: (cladribine + cytarabine + daunorubicin)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Published date:
12/04/2020
Excerpt:
For univariate and multivariate survival analyses, only patients who received first-line intensive treatment (anthracycline + cytarabine, 7 + 3 schedule) were selected….At diagnosis, no association with OS was observed; however, BCL2 levels above the AUC value (Supplementary Table S4) were significantly associated with worse PFS in the univariate analysis (HR 1.63, 95% CI 1–2.66, p = 0.05) and this behavior was marginally maintained in the multivariate analysis (HR 1.589, 95% CI 0.96–2.62, p = 0.07)....In conclusion, high BCL2 levels PI or at CR had an independent negative impact on patient outcome. Therefore, BCL2 expression is a dynamic marker that may be useful during AML patient follow up, and BCL2 levels at PI and/or CR may influence response to anti-BCL2 therapy.
DOI:
10.3390/diagnostics10121048